Sponsor pipeline

Johnson & Johnson / Janssen clinical trial pipeline

Get alerts when Johnson & Johnson / Janssen's trials change

206 active trials 97 recruiting 78 Phase 3 30 disease areas 65 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

48 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 37 with minor changes only.

Stopped

Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications · Children/Adolescents With Pulmonary MDR-TB

Recruitment suspended

Sponsor's reason: As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated bedaquiline exposure

Janssen Research & Development, LLCPhase 2 NCT02354014 Registry history of NCT02354014 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026
Notable

JNJ-81201887 (AAVCAGsCD59) Parent Studies · Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Primary endpoint(s) modified

Also in this update: Phase changed: Phase 2 → Phase 2/3

Janssen Research & Development, LLCPhase 2/3 NCT06635148 Registry history of NCT06635148 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Notable

TRIlogy-7 · Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) · NDMM For Whom Stem Cell Transplant is Not Planned

Recruitment opened

Also in this update: Trial sites expanded: 0 → 19 locations; and 1 more change in the last 30 days

Janssen Research & Development, LLCPhase 3 NCT07665450 Registry history of NCT07665450 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Notable

JNJ-101556143 · Metastatic Prostate Cancer

Recruitment opened

Also in this update: Trial sites expanded: 0 → 5 locations; Start date changed from estimate of Sep 28, 2026 to Sep 16, 2026

Janssen Research & Development, LLCPhase 2 NCT07832292 Registry history of NCT07832292 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Notable

Approved Contact Lenses (CR-6657)

Recruitment opened

Johnson & Johnson Vision Care, Inc.Not applicable NCT07819305 Registry history of NCT07819305 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Notable

ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal

Recruitment opened

Johnson & Johnson Vision Care, Inc.Not applicable NCT07788521 Registry history of NCT07788521 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Notable

GO-ON · Persistency of Guselkumab · Inflammatory Bowel Disease

Recruitment opened

Also in this update: Start date changed from estimate of Sep 18, 2026 to Sep 14, 2026

Janssen Research & Development, LLCNot specified NCT07822529 Registry history of NCT07822529 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Notable

VENTURA-LT · Aticaprant in Adult and Elderly · Major Depressive Disorder (MDD)

Results posted: Oct 6, 2026

Janssen Research & Development, LLCPhase 3 NCT05518149 Registry history of NCT05518149 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Notable

Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) · Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Results posted: Sep 28, 2026

Janssen Research & Development, LLCPhase 3 NCT04899336 Registry history of NCT04899336 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Notable

GusTaCon · Continued Use of Guselkumab · Crohn's Disease and Ulcerative Colitis in Real World Setting

Start date pushed from Sep 30, 2026 to Oct 30, 2026

Also in this update: Completion pushed from Sep 30, 2029 to Oct 30, 2029

Janssen Sciences Ireland UCNot specified NCT07746765 Registry history of NCT07746765 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Notable

Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process

Results posted: Sep 15, 2026

Johnson & Johnson Vision Care, Inc.Not applicable NCT06967129 Registry history of NCT06967129 on ClinicalTrials.gov (opens the registry)

Updated Sep 15, 2026

Show 37 trials with minor changes only

Minor

CAN3001 · PCI-32765 (Ibrutinib)

Enrollment closed, study ongoing

Also in this update: Final enrollment: 539 participants (planned 700)

Janssen Research & Development, LLCPhase 3 NCT01804686 Registry history of NCT01804686 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

TRIlogy-3 · JNJ-79635322 · Relapsed or Refractory Multiple Myeloma

Enrollment closed, study ongoing

Janssen Research & Development, LLCPhase 2 NCT07266441 Registry history of NCT07266441 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Enrollment closed, study ongoing

Also in this update: Completion moved earlier from Nov 21, 2028 to Feb 9, 2028; Final enrollment: 85 participants (planned 155)

Janssen Research & Development, LLCPhase 1 NCT06651229 Registry history of NCT06651229 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

14C-Bleximenib (Radiolabeled) · Acute Leukemia

Trial completed

Also in this update: Primary completion date changed from estimate of Sep 29, 2026 to Jul 21, 2026; Final enrollment: 6 participants (planned 10)

Janssen Research & Development, LLCPhase 1 NCT07295951 Registry history of NCT07295951 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

HLD-0915 (JNJ-101556143) · Metastatic Prostate Cancer

Primary and study completion pushed from Jul 11, 2028 to Aug 17, 2028

Janssen Research & Development, LLCPhase 1/2 NCT06800313 Registry history of NCT06800313 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Enrollment increased: 240 → 276 participants

And 2 more changes in the last 30 days

Janssen Research & Development, LLCPhase 1 NCT06768489 Registry history of NCT06768489 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Seltorexant as Monotherapy in Adults and Elderly · Major Depressive Disorder

Trial sites expanded: 39 → 45 locations

Janssen Research & Development, LLCPhase 3 NCT07573176 Registry history of NCT07573176 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

TRI Pro · Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration · Relapsed/Refractory Multiple Myeloma

Trial sites expanded: 9 → 38 locations

Janssen Research & Development, LLCPhase 2 NCT07589634 Registry history of NCT07589634 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

cAMeLot-2 · Bleximenib, Venetoclax and Azacitidine · Newly Diagnosed Acute Myeloid Leukemia (AML)

Trial sites expanded: 262 → 266 locations

Janssen Research & Development, LLCPhase 3 NCT06852222 Registry history of NCT06852222 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

TRIlogy-5 · JNJ-79635322 and Teclistamab · Relapsed or Refractory Multiple Myeloma

Trial sites expanded: 151 → 173 locations

Janssen Research & Development, LLCPhase 3 NCT07518186 Registry history of NCT07518186 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

KLK2-PASenger · Pasritamig With Docetaxel Versus Docetaxel · Metastatic Castration-Resistant Prostate Cancer

Trial sites expanded: 152 → 158 locations

Also in this update: Completion pushed from Jul 20, 2029 to Jun 7, 2030

Janssen Research & Development, LLCPhase 3 NCT07225946 Registry history of NCT07225946 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

AVENUE · Esketamine for Reduction of Symptoms of Major Depressive Disorder

Trial sites expanded: 39 → 44 locations

Janssen Research & Development, LLCPhase 3 NCT07227454 Registry history of NCT07227454 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

TRIlogy-4 · JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody · Relapsed or Refractory Multiple Myeloma

Trial sites expanded: 144 → 150 locations

Janssen Research & Development, LLCPhase 3 NCT07258511 Registry history of NCT07258511 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Esketamine Nasal Spray Versus Placebo Spray · Treatment-resistant Depression

Trial sites expanded: 15 → 22 locations

Janssen Research & Development, LLCPhase 3 NCT07716098 Registry history of NCT07716098 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

GARDENIA-SLE · Nipocalimab · Moderate to Severe Systemic Lupus Erythematosus

Trial sites expanded: 249 → 260 locations

Janssen Research & Development, LLCPhase 3 NCT07438496 Registry history of NCT07438496 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

CARTITUDE-10 · Ciltacabtagene Autoleucel

Trial sites expanded: 17 → 20 locations

Janssen Research & Development, LLCPhase 2 NCT07149857 Registry history of NCT07149857 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

AmiNA · Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy · Resectable EGFR-Mutated NSCLC

Trial sites expanded: 20 → 23 locations

Janssen Research & Development, LLCPhase 2 NCT07586202 Registry history of NCT07586202 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

JNJ-88549968 · Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Trial sites expanded: 41 → 44 locations

Janssen Research & Development, LLCPhase 1 NCT06150157 Registry history of NCT06150157 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

MajesTEC-3 · Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) · Relapsed or Refractory Multiple Myeloma

Primary completion moved earlier from Sep 15, 2025 to Aug 1, 2025

Janssen Research & Development, LLCPhase 3 NCT05083169 Registry history of NCT05083169 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Adjunctive Treatment With Seltorexant in Adult and Elderly · Major Depressive Disorder and Insomnia Symptoms

Completion pushed from Apr 15, 2027 to Dec 15, 2027

Janssen Research & Development, LLCPhase 3 NCT06559306 Registry history of NCT06559306 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Nipocalimab · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completion pushed from Jul 11, 2028 to Nov 27, 2028

Janssen Research & Development, LLCPhase 2/3 NCT05327114 Registry history of NCT05327114 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

MARIPOSA-2 · Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy · Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Completion pushed from Nov 30, 2027 to Jul 3, 2028

Janssen Research & Development, LLCPhase 3 NCT04988295 Registry history of NCT04988295 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

MAGNITUDE · Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone · Metastatic Prostate Cancer

Completion pushed from Feb 27, 2027 to Dec 31, 2027

Janssen Research & Development, LLCPhase 3 NCT03748641 Registry history of NCT03748641 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

THOR · Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab · Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Completion pushed from Dec 31, 2026 to Dec 31, 2027

Janssen Research & Development, LLCPhase 3 NCT03390504 Registry history of NCT03390504 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

OrigAMI-1 · Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy · Advanced or Metastatic Colorectal Cancer

Completion pushed from Oct 31, 2030 to May 11, 2031

Janssen Research & Development, LLCPhase 1/2 NCT05379595 Registry history of NCT05379595 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Completion pushed from Mar 31, 2027 to Sep 30, 2027

Janssen Research & Development, LLCPhase 2 NCT05663866 Registry history of NCT05663866 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

MonumenTAL-2 · Talquetamab With Other Anticancer Therapies · Multiple Myeloma

Completion pushed from Apr 7, 2027 to Dec 31, 2027

Janssen Research & Development, LLCPhase 1 NCT05050097 Registry history of NCT05050097 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

TRIMM-3 · Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor · Relapsed or Refractory Multiple Myeloma

Completion pushed from May 3, 2027 to Dec 31, 2027

Janssen Research & Development, LLCPhase 1 NCT05338775 Registry history of NCT05338775 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

JNJ-86974680 · Advanced Non-small Cell Lung Cancer

Completion moved earlier from Jun 7, 2029 to Nov 30, 2027

Johnson & Johnson Enterprise Innovation Inc.Phase 1 NCT06116786 Registry history of NCT06116786 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies · Multiple Myeloma

Completion pushed from Apr 7, 2027 to Dec 31, 2027

Janssen Research & Development, LLCPhase 1 NCT04108195 Registry history of NCT04108195 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Primary completion date changed from estimate of Nov 16, 2026 to Sep 2, 2026

Janssen Research & Development, LLCPhase 1 NCT06618001 Registry history of NCT06618001 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Completion pushed from Oct 30, 2028 to Dec 29, 2028

Janssen Research & Development, LLCPhase 1 NCT06788509 Registry history of NCT06788509 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

CHRYSALIS · Amivantamab, a Human Bispecific EGFR and cMet Antibody, · Advanced Non-Small Cell Lung Cancer

Completion pushed from Dec 31, 2026 to Dec 31, 2027

Janssen Research & Development, LLCPhase 1 NCT02609776 Registry history of NCT02609776 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Completion pushed from Mar 3, 2027 to Jun 30, 2027

Janssen Research & Development, LLCPhase 1 NCT05453903 Registry history of NCT05453903 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

HLD-0117 · JNJ-101684362 (HLD-0117) · Metastatic Breast Cancer

Interventions modified

Janssen Research & Development, LLCPhase 1 NCT07524855 Registry history of NCT07524855 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

Nova-sTAR · Real-World Use and Outcomes of TAR-200 · Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

Completion pushed from Oct 9, 2029 to Jun 28, 2030

Janssen Research & Development, LLCNot specified NCT07309445 Registry history of NCT07309445 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

QOLIBRI · Benefits of Individual Physical Activity Intervention on Health-related Quality of Life · Chronic Lymphocytic Leukemia

Completion pushed from Oct 29, 2027 to Nov 30, 2027

Janssen Cilag S.A.S.Not specified NCT06299540 Registry history of NCT06299540 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First posted	Trial	Phase	Status
2026-10-01	NCT07851207 A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel…		Not Yet Recruiting
2026-09-21	NCT07832292 A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer	Phase 2	Recruiting
2026-09-16	NCT07822529 A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory…		Recruiting
2026-09-14	NCT07819305 Evaluation of Approved Contact Lenses (CR-6657)		Recruiting

Active trials by phase

Phase 1		47
Phase 1/2		12
Phase 2		30
Phase 2/3		7
Phase 3		71
Phase 4		6

Not charted: 33 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 206

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT07654751	A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating…	Psoriasis	Recruiting	2026-10-05
NCT05201781	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel	Multiple Myeloma	Recruiting	2026-09-25
NCT07310095	A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's…	Crohn Disease	Recruiting	2026-09-25
NCT07141004	A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants…	Arthritis, Psoriatic	Recruiting	2026-08-28
NCT04929210	A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active…	Arthritis, Psoriatic	Active, Not Recruiting	2026-09-25
NCT07030517	A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and…	Multiple Myeloma	Active, Not Recruiting	2026-09-25
Phase 3
NCT07665450	A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and…	Multiple Myeloma	Recruiting	2026-10-06
NCT07573176	A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major…	Depressive Disorder, Major	Recruiting	2026-10-01
NCT06919965	A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants…	Non-Muscle Invasive Bladder Neoplasms	Recruiting	2026-09-28
NCT04892173	JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Carcinoma, Squamous Cell	Recruiting	2026-09-25
NCT05552222	A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and…	Multiple Myeloma	Recruiting	2026-09-25
NCT05912517	A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus…	Hemolytic Disease of the Fetus and Newborn	Recruiting	2026-09-25
NCT05923073	A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active…	Crohn's Disease	Recruiting	2026-09-25
NCT06319820	A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in…	Non-Muscle Invasive Bladder Neoplasms	Recruiting	2026-09-25
NCT06449651	A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune…	Thrombocytopenia, Neonatal Alloimmune	Recruiting	2026-09-25
NCT06533098	A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of…	Thrombocytopenia, Neonatal Alloimmune	Recruiting	2026-09-25
NCT06559306	Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants…	Depressive Disorder, Major	Recruiting	2026-09-25
NCT06662786	A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI…	Colorectal Neoplasms	Recruiting	2026-09-25
NCT06663332	A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants	Crohns Disease	Recruiting	2026-09-25
NCT06750094	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in…	Colorectal Neoplasms	Recruiting	2026-09-25
NCT06807424	A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in…	Arthritis, Psoriatic	Recruiting	2026-09-25
NCT06852222	A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With…	Leukemia, Myeloid, Acute	Recruiting	2026-09-25
NCT07164443	A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line…	Metastatic Castration-resistant Prostatic Neoplasms	Recruiting	2026-09-25
NCT07196748	A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to…	Colitis, Ulcerative	Recruiting	2026-09-25
NCT07217587	Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized…	Myasthenia Gravis	Recruiting	2026-09-25

See all 206 active Johnson & Johnson / Janssen trials with filters →

Disease areas by active trials, top 10 of 30

Multiple Myeloma (31) · Crohn's Disease (22) · Prostate Cancer (22) · Ulcerative Colitis (20) · Lung Cancer (17) · Non-Small Cell Lung Cancer (NSCLC) (17) · Bladder Cancer (13) · Leukemia (12) · Psoriatic Arthritis (12) · Psoriasis (11)

Get alerts when Johnson & Johnson / Janssen's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free